- An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Chest (2013-05-08)
Nicholas G Wysham, Donald R Sullivan, Gopal Allada
PMID23648912
ABSTRACT
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.